文献速递白血病

机器学习整合基因组特征实现超越原发与继发性急性髓系白血病的分子亚分类

Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia.
PubMed 文献 · Blood · 2021-01-01

该研究整合6788例急性髓系白血病(AML)患者的多中心细胞遗传学和基因测序数据,采用标准方法与机器学习分析。传统监督分析预测病理形态学分类的交叉验证准确性有限,而无监督贝叶斯潜在类别方法识别出4个预后不同的基因组簇,交叉验证准确率达97%,并提供了开放获取的分子分类方案。

要点

  • 传统形态学分类与基因组特征相关性有限,机器学习可实现基于基因组特征的AML分子亚分类。
  • 无监督分析识别出4个预后不同的基因组簇,交叉验证准确率97%。
  • 该分子分类方案开放获取,内部和外部验证均支持其有效性。

核心结论

  • 机器学习方法可定义新的基因组AML亚类,传统病理形态学定义可能较少反映重叠的发病机制。

研究设计与样本

  • 多中心队列研究,纳入6788例AML患者,整合细胞遗传学和基因测序数据,采用标准方法和机器学习分析。

主要发现

  • 标准监督分析使用分子模式预测传统病理形态学AML分类的交叉验证准确性有限。
  • 无监督贝叶斯潜在类别方法识别出4个预后不同的基因组簇。
  • 提取驱动每个簇的不变基因组特征用于基因组亚分类,交叉验证准确率达97%。
  • 由分子特征定义的AML亚类与当前病理形态学和临床定义的AML亚型有重叠。

临床怎么用

  • 提供开放获取的AML分子分类方案,可用于患者分子亚分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although genomic alterations drive the pathogenesis of acute myeloid leukemia (AML), traditional classifications are largely based on morphology, and prototypic genetic founder lesions define only a small proportion of AML patients. The historical subdivision of primary/de novo AML and secondary AML has shown to variably correlate with genetic patterns. The combinatorial complexity and heterogeneity of AML genomic architecture may have thus far precluded genomic-based subclassification to identify distinct molecularly defined subtypes more reflective of shared pathogenesis. We integrated cytogenetic and gene sequencing data from a multicenter cohort of 6788 AML patients that were analyzed using standard and machine learning methods to generate a novel AML molecular subclassification with biologic correlates corresponding to underlying pathogenesis. Standard supervised analyses resulted in modest cross-validation accuracy when attempting to use molecular patterns to predict traditional pathomorphologic AML classifications. We performed unsupervised analysis by applying the Bayesian latent class method that identified 4 unique genomic clusters of distinct prognoses. Invariant genomic features driving each cluster were extracted and resulted in 97% cross-validation accuracy when used for genomic subclassification. Subclasses of AML defined by molecular signatures overlapped current pathomorphologic and clinically defined AML subtypes. We internally and externally validated our results and share an open-access molecular classification scheme for AML patients. Although the heterogeneity inherent in the genomic changes across nearly 7000 AML patients was too vast for traditional prediction methods, machine learning methods allowed for the definition of novel genomic AML subclasses, indicating that traditional pathomorphologic definitions may be less reflective of overlapping pathogenesis.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Awada H, Durmaz A, Gurnari C, et al. Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. Blood. 2021. PMID: 34075412. doi:10.1182/blood.2020010603

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。